




Disclosures


- Co-PI for the NIH-Moderna mRNA-1273 study
 - All funding for my activities from NIAID-NIH

























Phase 3: Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults to Prevent COVID-19


- N= 30,000
 - 1:1 vaccine: Placebo
 - Double blind, placebo controlled
 - 2 vaccinations (d1 and d29), follow-up 2 years
 - High risk for SARS-CoV-2 infection and increased risk for complications from infection
 - Population studied needs to represent the country and those disproportionately impacted
- Primary Outcomes
 - Efficacy
 - COVID-19 starting 14 days after second dose (d42)
 - Safety
- Key Statistical Assumptions
 - COVID-19 incidence rate over 6 months 0.75% in placebo group
 - Target Vaccine Efficacy (VE) 60% with lower bound 95% CI >30%


CoVPN 3001, NIH-Moderna mRNA-1273-P301, NCT04470427


	Table 1. Demographic and Clinical Characteristics at Baseline.*			
ORIGINAL ARTICLE	Characteristics	Placebo (N=15,170)	mRNA-1273 (N=15,181)	Total (N=30,351)
	Sex — no. of participants (%)			
	Male	8,062 (53.1)	7,923 (52.2)	15,985 (52.7)
Efficacy and Safety of the mRNA-1273	Female	7,108 (46.9)	7,258 (47.8)	14,366 (47.3)
SARS-CoV-2 Vaccine	Mean age (range) — yr	51.3 (18-95)	51.4 (18-95)	51.4 (18-95)
Shilo Covez vaccine	Age category and risk for severe Covid-19 — no. of participants (%)†			
L.R. Baden, H.M. El Sahly, B. Essink, K. Kotloff, S. Frey, R. Novak, D. Diemert,	18 to <65 yr, not at risk	8,886 (58.6)	8,888 (58.5)	17,774 (58.6)
S.A. Spector, N. Rouphael, C.B. Creech, J. McGettigan, S. Khetan, N. Segall,	18 to <65 yr, at risk	2,535 (16.7)	2,530 (16.7)	5,065 (16.7)
Solis, A. Brosz, C. Fierro, H. Schwartz, K. Neuzil, L. Corey, P. Gilbert, H. Janes,	≥65 yr	3,749 (24.7)	3,763 (24.8)	7,512 (24.8)
D. Follmann, M. Marovich, J. Mascola, L. Polakowski, J. Ledgerwood, B.S. Graham, H. Bennett, R. Pajon, C. Knightly, B. Leav, W. Deng, H. Zhou,	Hispanic or Latino ethnicity — no. of participants (%) ‡			-
S. Han, M. Ivarsson, J. Miller, and T. Zaks, for the COVE Study Group*	Hispanic or Latino	3,114 (20.5)	3,121 (20.6)	6,235 (20.5)
5. That, W. Wasson, J. Willer, and T. Zaka, for the Core study croup	Not Hispanic or Latino	11,917 (78.6)	11,918 (78.5)	23,835 (78.5)
	Not reported and unknown	139 (0.9)	142 (0.9)	281 (0.9)
Enrollment: July 27 – Oct 23	Race or ethnic group — no. of participants (%) \$			
	White	11,995 (79.1)	12,029 (79.2)	24,024 (79.2)
 N= 30,420 randomized 	Black or African American	1,527 (10.1)	1,563 (10.3)	3,090 (10.2)
 30,351 received dose 1 	Asian	731 (4.8)	651 (4.3)	1,382 (4.6)
 >96% received dose 2 	American Indian or Alaska Native	121 (0.8)	112 (0.7)	233 (0.8)
 >96% received dose 2 	Native Hawaiian or Other Pacific Islander	32 (0.2)	35 (0.2)	67 (0.2)
 29,148 (95.8%) mITT 	Multiracial	321 (2.1)	315 (2.1)	636 (2.1)
	Other	316 (2.1)	321 (2.1)	637 (2.1)
 28,207 (92.9%) per-protocol 	Not reported and unknown	127 (0.8)	155 (1.0)	282 (0.9)
	Baseline SARS-CoV-2 status — no. of participants (%)§			
As of Nov 25 (data cut off)	Negative	14,598 (96.2)	14,550 (95.8)	29,148 (96.0)
	Positive	337 (2.2)	343 (2.3)	680 (2.2)
 Median f/u 63 days post dose 2 (range 0-97) 	Missing data	235 (1.5)	288 (1.9)	523 (1.7)
, , , , , , , , , , , , , , , , , , , ,	Baseline RT-PCR test — no. of participants (%)			
	Negative	14,923 (98.4)	14,917 (98.3)	29,840 (98.3)
-	Positive	95 (0.6)	87 (0.6)	182 (0.6)
All the second	Missing data	152 (1.0)	177 (1.2)	329 (1.1)
	Baseline bAb anti-SARS-CoV-2 assay — no. of participants (%)			
NAME OF THE OWNER OF	Negative	14,726 (97.1)	14,690 (96.8)	29,416 (96.9)
0/10-19	Positive	303 (2.0)	305 (2.0)	608 (2.0)
evention Network	Missing data	141 (0.9)	186 (1.2)	327 (1.1)














Nov 15: NIAID DSMB meeting Nov 16: Press release Dec 18: VRBPAC meeting Dec 19: FDA action – EUA Dec 20: ACIP/CDC Guidance Dec 21: Vaccine shipped Key question: What to do with study volunteers Study is NOT over (yet EUA/clinical vaccine available) Asymptomatic infection, viral shedding/carriage, durability/waning immunity, protection in sub-groups







ffectiveness of an Inactivated SARS-Co	oV-2						
Vaccine in Chile							
Nejandro Jara, Ph.D., Eduardo A. Undurraga, Ph.D., Cecilia González, Fabio Paredes, M.Sc., Tomás Fonteolila, M.S.C., Gonzolo Jara, B.S. Alejandra Pizarco, M.D., Johanna Acevedo, M.S., Katherinne Leo, B. Francisco Leon, M.B.A., Carlos Sans, B.S.E., Paulina Leighton, B.S. mela Suárez, B.S.E., Herberbor Carcia-Escorza, M.S., and Rafael Arac	E., S.E., E.,	oronaVac Vaccine i	n Preventing Co	ovid-19 Outcomes in C	Overall Study Coh	ort. According to Imn	nunization Statu
	Outcome and Immunization Status	Study Cohort		is with Covid-19		ccine Effectiveness (
		No. of Person-Days	No. of Persons	Incidence Rate	Analysis Adjusted for Sex and Age	Analysis Adjusted for All Covariates†	Stratified Analysis‡
				no. of events/ 1000 person-days		percent	
	Covid-19						
	Unvaccinated	614,868,240	185,633	0.3019			
	Partially immunized	69,788,352	20,8 <mark>6</mark> 5	0.2990	8.0 (6.5–9.4)	15.5 (14.2–16.8)	17.2 (15.8–18.6)
	Fully immunized	91,671,797	12,286	0.1340	61.2 (60.3–62.0)	65.9 (65.2–66.6)	63.7 (62.8–64.6)
	Hospitalization						
	Unvaccinated	620,894,706	18,034	0.0290		_	<u>. </u>
	Partially immunized	70,690,796	3,370	0.0477	31.4 (28.6–34.0)	37.4 (34.9–39.9)	40.3 (37.6–42.8)
	Fully immunized	92,445,333	1,462	0.0158	86.0 (85.1-86.8)	87.5 (86.7–88.2)	86.5 (85.6-87.4)


bitiliozoz dotta is tuccine in na	lolescents					
Robert W. Frenck, Jr., M.D., Nicola P. Klein, M.D., Ph.D., Nicho Alejandra Gurtman, M.D., Judith Absalon, M.D., Stephen L John L. Perez, M.D., Emmanuel B. Walter, M.D., Shelly Se Ruth Bailey, B.Sc., Kena A. Swanson, Ph.D., Hua Ma, Ph.D., Kenneth Koury, Ph.D., Warren V. Kalina, Ph.D., David Co	ockhart, D.M.,		say Results 1 Mont	h after Dose 2 of B	NT162b2 among P	Participants
Timothy Jennings, D.O., Donald M. Brandon, M.D., Stephen J Özlem Türeci, M.D., Dina B. Tresnan, D.V.M., Ph.D., Susan Philip R. Dormitzer, M.D., Ph.D., Uğur Şahin, M.D., Kathrin L and William C. Gruber, M.D., for the C4591001 Clinical T		o. of Geor ipants	Geometric Mean 50% Neutralizing Titer (95% CI)†		Geometric Mean Ratio (95% 12 to 15 Yr vs. 16 to 25 Yr;	
and Wintam C. Graber, M.D., for the Crossfort Clinical F	12–15 yr 1	90	1239.5 (1095.5-14	02.5)	1.76 (1.47	-2.10)
	16–25 yr 1	70	705.1 (621.4-800	.2)	5-6	
	Efficacy End Point†	cacy End Point [°] BNT162b2		Pla	cebo	% Vaccine Efficacy (95% CI)‡
		No. of Participants with Event/Total No.§	Surveillance Time (No. at Risk)¶	No. of Participants with Event/Total No.§	Surveillance Time (No. at Risk)¶	
	Covid-19 occurrence at least 7 days after dose 2 in par- ticipants without evidence of previous infection	0/1005	0.154 (1001)	16/978	0.147 (972)	100 (75.3–100)
	Covid-19 occurrence at least 7 days after dose 2 in par- ticipants with or without evi-	0/1119	0.170 (1109)	18/1110	0.163 (1094)	100 (78.1–100)


Where Are We Today

- mRNA (?Booster doses)
 - Pfizer FDA EUA 12/11
 - DSMB review: Efficacy data 11/9
 - Cold chain considerations
 - Up to 1.3 billion by end 2021
 - Moderna FDA EUA 12/18
 - DSMB review: efficacy data 11/16
 - Cold chain less challenging ok at 2-8C for 30 days
 - Up to 1 billion doses by end 2021
- Viral Vector
 - AstraZeneca
 - DSMB review: efficacy data 11/23
 - Use in UK and elsewhere
 - Janssen FDA EUA Feb 27
 - Phase 3 trial ongoing
 - Single and multiple doses regimens being studied



ORIGINAL ARTICLE	Subgroup	No. of Patients			Vaccine Effectiveness (95% CI) %		
	Effectiveness against hospitalization						
Effectiveness of Covid-19 Vaccines	BN1162b2 vaccine						
	Unvaccinated (referent)	20,406	3695 (18.1)				
n Ambulatory and Inpatient Care Settings	Partially vaccinated						
	Dose 1	1,444	140 (9.7)		•		33 (18-46)
.G. Thompson, E. Stenehjem, S. Grannis, S.W. Ball, A.L. Naleway, T.C. Ong,	Dose 2	1,348	57 (4.2)			H+++	73 (63-81)
M.B. DeSilva, K. Natarajan, C.H. Bozio, N. Lewis, K. Dascomb, B.E. Dixon,	Fully vaccinated — 2 doses	8,500	163 (1.9)			(e)	87 (85–90)
J. Birch, S.A. Irving, S. Rao, E. Kharbanda, J. Han, S. Reynolds, K. Goddard,	mRNA-1273 vaccine Unvaccinated (referent)	20.405	3695 (18.1)				
	Partially vaccinated	20,406	3693 (18.1)				
N. Grisel, W.F. Fadel, M.E. Levy, J. Ferdinands, B. Fireman, J. Arndorfer,	Dose 1	1.639	91 (5.6)				68 (59-75)
. Valvi, E.A. Rowley, P. Patel, O. Zerbo, E.P. Griggs, R.M. Porter, M. Demarco,	Dose 2	1,035	50 (4.4)				74 (64-82)
Blanton, A. Steffens, Y. Zhuang, N. Olson, M. Barron, P. Shifflett, S.J. Schrag,	Fully vaccinated — 2 doses	6,374	95 (1.5)			Hel	91 (89-93)
J.R. Verani, A. Fry, M. Gaglani, E. Azziz-Baumgartner, and N.P. Klein	Ad26.COV2.S vaccine	0,071	55 (2.5)				
J.N. Verani, A. Hy, W. Gagiani, L. Azziz-Daunigarmer, and W.F. Kieni	Unvaccinated (referent)	10,761	2006 (18.6)				
	Fully vaccinated 1 dose	707	30 (4.2)				68 (50-79)
- · · · · •	Effectiveness against ICU admission		10.0				10.00
CoV-Inf	BNT162bz vaccine or mRNA-1273 vaccine						
	Unvaccinated (referent)	4,024	692 (17.2)				
 Asymptomatic+ 	Partially vaccinated						
, symptomatic .	Dose 1	512	39 (7.6)		•		56 (35-70)
0.1/0	Dose 2	388	15 (3.9)			•	75 (58-86)
CoV-Dis	Fully vaccinated — 2 doses	2,359	38 (1.6)			H	90 (86-93)
	Effectiveness against emergency department or urgent care visit	>					
 Mild/mod 	BNT162b2 vaccine						
	Unvaccinated (referent)	11,812	2847 (24.1)				
 Severe – hospitalization, death 	Partially vaccinated						
	Dose 1	912	88 (9.6)				58 (46-68)
CoV-Trans	Dose 2	711	31 (4.4)				82 (74-88)
	Fully vaccinated — 2 doses	3,589	105 (2.9)			H+I	89 (85-91)
Como illana a DCD anna la ma	mRNA-1273 vaccine						
 Surveillance – PCR, serology 	Unvaccinated (referent)	11,812	2847 (24.1)				
	Partially vaccinated						
	Dose 1	1,008	67 (6.6)		2	H+++	73 (64–79)
	Dose 2	558	35 (6.3)		E	•	72 (59-81)
	Fully vaccinated — 2 doses	2,476	49 (2.0)			H	92 (89-94)
	Ad26.COV2.S vaccine		7700 (25 0)				
	Unvaccinated (referent) Fully vaccinated — 1 dose	8,461 456	2200 (26.0) 29 (6.4)		15		73 (59-82)
	runy vaccinated — 1 dose	430	23 (0.4)	0.0 25.0	50.0	75.0 1	00.0
				0.0 25.0	50.0	/5.0 1	100.0
	Figure 1. Estimated Vaccine Effectivene		DE CAV 2 1-6-			Cardina an	







Understanding VE (Vaccine Efficacy)


- CoR Correlate of Risk
- CoP Correlate of Protection
- Sieve Analysis
- Mechanism(s) of protection
- Immunologic bridging
 - Key populations,
 - Future generation vaccines
- Strain Variation

OVE		No. Cases/ No. At-Risk*		D-fold Increase	P-Value	FDR- adjusted p-value**	FWER- adjusted
nmunologic Marker			Point Es	. ((2-Sided)		
nti Spike IgG (BAU/r		47/14,064	0.66	(0.50, 0.88)	0.005	0.014	0.010
nti RBD IgG (BAU/m		47/14,064	0.57	(0.40, 0.82)	0.002	0.008	0.008
seudovirus-nAb ID50			0.42	(0.27, 0.65)	< 0.001	0.002	0.003
seudovirus-nAb ID80			0.35	(0.20, 0.61)	< 0.001	0.003	0.003
eeline covariatee adjuete 0 days post Day 57 visit.	d for: baselin	e risk score, At F	liek etatue, Co	ommunity of color e	tatue. Maximu	ım failure eve	nt time
Io. at-risk = estimated nui periencing the COVID-19 to observed COVID-19 en- iccause the 47 includes all FDR (false discovery rate it of p-values both for qua- rmutation method (10.00	endpoint thr dpoint starting vaccine brea)-adjusted p- intitative mark	ough 6 days pos 7 days post Da kthrough cases values and FWE	t Day 57 visit; y 57 visit. The including the R (family-wise	no. cases = estima count 47 differs fro 11 without Day 1, 2 error rate)-adjuste	ated number o om 36 (Figure 9, 57 antibody d p-values are	f this cohort (1, Table 1), marker data computed c	ver the
		Bindir	na Antibody	to Spike: Day	57		
			.g	(0 0p.1107 0 0)	••		
iroup Il Vaccine	No. Events 47	,				HR (95%	
ivaccine ⊒e ≥ 65	4/					0.66 (0.50	
e < 65	40		•			0.52 (0.19	
isk	40					0.68 (0.51	
usk Latrisk	32					0.63 (0.44	
mm. of color	12					0.15 (0.06	
ite Non-Hispanic	35					0.71 (0.52	
ale	23			_		0.26 (0.07	
male	24					0.71 (0.53	
			1 1				,,
		0 0.2 0.4	0.6 0.8 Haz	1 1.2 1.4 zard Ratio	1.6 1.8	2	
		nhibitory Dilu	tion Pseud	ovirus Neutraliz	ation Titer:	Day 57	
2	50% I						
	50% I No. Even					HR (95%	CI)
roup						HR (95%	
I Vaccine	No. Even						7, 0.65)
IVaccine ge ≥ 65	No. Even 47					0.42 (0.2	7, 0.65) 0, 1.12)
IVaccine ge ≥ 65 ge < 65	No. Even 47 7					0.42 (0.2	7, 0.65) 0, 1.12) 6, 0.69)
Vaccine je ≥ 65 je < 65 risk	No. Even 47 7 40					0.42 (0.2 0.34 (0.1 0.42 (0.2	7, 0.65) 0, 1.12) 6, 0.69) 8, 1.02)
Vaccine ye ≥ 65 ye < 65 risk ot at risk omm. of color	No. Even 47 7 40 15 32 12					0.42 (0.2 0.34 (0.1 0.42 (0.2 0.53 (0.2 0.32 (0.1 0.45 (0.1	7, 0.65) 0, 1.12) 6, 0.69) 8, 1.02) 7, 0.62) 2, 1.65)
roup III Vaccine ge ≥ 65 ge < 65 t risk ot at risk onm. of color /hite Non-Hispanic	No. Even 47 7 40 15 32 12 35					0.42 (0.2 0.34 (0.1 0.42 (0.2 0.53 (0.2 0.32 (0.1	7, 0.65) 0, 1.12) 6, 0.69) 8, 1.02) 7, 0.62) 2, 1.65)
roup ge ≥ 65 ge < 65 t risk ot at risk omm. of color /hite Non-Hispanic lale	No. Even 47 7 40 15 32 12 35 23		· · · · · · · · · · · · · · · · · · ·			0.42 (0.2 0.34 (0.1 0.42 (0.2 0.53 (0.2 0.32 (0.1 0.45 (0.1	7, 0.65) 0, 1.12) 6, 0.69) 8, 1.02) 7, 0.62) 2, 1.65) 4, 0.67)
roup ge ≥ 65 ge < 65 t risk ot at risk omm. of color /hite Non-Hispanic lale	No. Even 47 7 40 15 32 12 35		· · · · · · · · · · · · · · · · · · ·			0.42 (0.2 0.34 (0.1 0.42 (0.2 0.53 (0.2 0.32 (0.1 0.45 (0.1 0.40 (0.2	7, 0.65) 0, 1.12) 6, 0.69) 8, 1.02) 7, 0.62) 2, 1.65) 4, 0.67) 0, 0.54)
3roup UI Vaccine (ge ≥ 65 trisk Vota trisk Somm. of color White Non-Hispanic Aale eemale	No. Even 47 7 40 15 32 12 35 23			1 12 14	16 18	0.42 (0.2 0.34 (0.1 0.42 (0.2 0.53 (0.2 0.32 (0.1 0.45 (0.1 0.45 (0.1 0.40 (0.2 0.23 (0.1	7, 0.65) 0, 1.12) 6, 0.69) 8, 1.02) 7, 0.62) 2, 1.65) 4, 0.67) 0, 0.54)











mmercial and 2 laboratory assays	Table 4. Assay se					
51 PCR+ Covid-19 cases	Assay	Days PSO	Total No. of PCR-positive samples	No. testing positive	Percentage	95% CI
	Epitope IgG	<8 days	26	11	42.31	25.54-61.05
		8-14 days	77	65	84.42	74.71-90.85
		15-21 days	65	60	92.31	83.22-96.67
		>21 days	83	71	85.54	76.41-91.53
		Overall	251	207	82.47	77.29-86.67
	Epitope IgM	<8 days	26	8	30.77	16.50-49.99
	1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.	8-14 days	77	43	55.84	44.74-66.39
		15-21 days	65	41	63.08	50.92-73.77
		>21 days	83	26	31.33	22.36-41.94
		Overall	251	118	47.01	40.93-53.18
	Ragon/MGH IgG ^a	<8 days	26	5	19.23	8.51-37.88
		8-14 days	77	44	57.14	46.01-67.60
		15-21 days	65	52	80.00	68.73-87.92
		>21 days	83	61	73.49	63.11-81.80
		Overall	251	162	64.54	58.45-70.20
	Roche ^b	<8 days	26	13	50.00	32.06-67.94
		8-14 days	77	62	80.52	70.31-87.82
		15-21 days	65	59	90.77	81.29-95.70
		>21 days	83	74	89.16	80.66-94.19
		Overall	251	208	82.87	77.72-87.03
	Simoa (Early) ^c	<8 days	26	15	57.69	38.95-74.46
		8-14 days	77	72	93.51	85.68-97.19
		15-21 days	65	65	100.00	94.42-100.00
		>21 days	83	79	95.18	88.25-98.11
		Overall	251	231	92.03	88.01-94.78



Breakthrough (delta) Covid-19 Infections: COVE Trial Covid-19 Cases and Incidence Rates After mRNA-1273 Vaccination

During July 1st to August 27, 2021 in the Modified Intent-to-Treat Population

Covid-19 Cases1 Cases n Person-yr Rate/J000 Person-yr Person-yr Rate/J000 Person-yr Reduction of observed incidence rate % (95% CI) All cases 162 2102 77.1 88 1796 49.0 36.4 (17.1-51.5) 218-c65 yr 136 1558 87.3 68 1289 52.8 39.6 (18.6-55.5) 265 yr 26 544 47.8 20 507 39.5 17.4 (-53.9-56.3) Severe 13 2102 6.2 6 1796 3.3 46.0 (-52.4-83.2) 218-c65 yr 7 1558 4.5 4 1289 3.1 30.9 (-171.7-85.2) 265 yr 7 1558 4.5 4.0 1289 3.1 30.9 (-171.7-85.2) 2c5 yr 7 1558 4.5 4.0 1289 3.1 30.9 (-171.7-85.2)
218-<65 yr
265 yr 26 544 47.8 20 507 39.5 17.4 (-53.9-56.3) Severe 13 2102 6.2 6 1796 3.3 46.0 (-52.4-83.2) 218-<65 yr
Severe 13 2102 6.2 6 1796 3.3 46.0 (-52.4-83.2) >18-<65 yr 7 1558 4.5 4 1289 3.1 30.9 (-171.7-85.2)
218-<65 yr 7 1558 4.5 4 1289 3.1 30.9 (-171.7-85.2)
265 yr 6 544 11.0 2 507 3.9 64.2 (-100.2-96.5)



Boosters

- Goal
 - Infection, illness, severe illness/death
 - Use CoP for a 'protective immunologic level'?
 Vary by vaccine platform?
- Variants
 - Beta, delta, mu,...
- Scenarios
 - Initial vaccine:
 - Dose
 - Heterologous/homologous delivery system
 - Heterologous/homologous insert
 - Time interval
- Benefit
 - CoV-Inf, CoV-Dis, Cov-Dis-severe, CoV-Trans
 - By risk group
 - Illness age, co-morbidities
 - Risk of acquisition healthcare workers

Questions Before US
 Efficacy shown in under a year! ~95% for molecularly confirmed symptomatic Covid-19 What about: acquisition, transmission
 How much data do we need to judge safety? Phase 3 trials (~38,000 participants), median follow-up > 6 months post receipt full vaccination regimen Less common (e.g., allergy) and longer term safety (>1 year, etc.)
 What about? Special populations: children, pregnancy, immunocompromised patients Those with prior SARS-CoV-2 infection Immunity – duration, development CoR/CoP (approval for next generation vaccines) Impact of viral evolution – variants of concern (VOCs): alpha, beta, delta
 How do we prioritize distribution? Increase supply At risk for acquisition, for severe disease Global equity
 How do we compare EUA vaccines and impact on vaccine development? As more vaccines are shown to be efficacious - how do we choose; and timing of availability Can vaccines be interchanged
Where do booster doses fit in? Define benefit Primary series, dose, interval/timing, insert

Community acceptance/ Vaccine Hesitancy

How do we gain trust

Acknowledgements

- Many, many partners
 - Study teams across the nation/globe
 - NIH-NIAID, CoVPN, BARDA, OWS
 - Industry: Moderna, Pfizer, AZ, J+J, Novavax, Sanofi
 - Regulators, safety oversight process: FDA, DSMB, IRBs
 - Investigators and associated teams
- Community
 - Local and global
- Volunteers
 - >>100,000



COVID-19